CLPTMEDIUM SIGNALFINANCIAL10-K

ClearPoint Neuro shows revenue growth but substantially wider losses as SG&A expenses meaningfully expanded while interest costs were nearly eliminated.

The company appears to be investing heavily in growth with SG&A expenses rising faster than revenue gains, resulting in deeper operating losses despite improved gross margins. The dramatic reduction in interest expense suggests debt paydown or refinancing, while the substantial increase in current assets indicates a stronger liquidity position.

Comparing 2026-03-17 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

ClearPoint delivered solid revenue growth of 18% with gross profit expanding at a similar pace, indicating stable underlying margins. However, operating losses widened as SG&A expenses grew notably faster than revenue, more than offsetting the gross profit gains. The balance sheet strengthened considerably with current assets roughly doubling, likely providing greater financial flexibility for the company's growth investments.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-91.7%
$973K→$81K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Assets
Balance Sheet
+90.6%
$33.4M→$63.6M

Current assets grew 90.6% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+89.8%
$275K→$522K

Capital expenditure jumped 89.8% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
+39%
$4.7M→$6.5M

Receivables surged 39% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

SG&A Expense
P&L
+37.5%
$12.0M→$16.5M

SG&A up 37.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Net Income
P&L
-35%
-$18.9M→-$25.5M

Net income declined 35% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-22.4%
-$19.7M→-$24.2M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Inventory
Balance Sheet
+21.8%
$6.9M→$8.4M

Inventory built 21.8% — monitor whether demand supports this build or if write-downs may follow.

Gross Profit
P&L
+18.7%
$19.1M→$22.7M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+17.8%
$31.4M→$37.0M

Revenue growing 17.8% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-02-26
ADDED
60 Trademarks, Trade Names and Service Marks ClearPoint Neuro , ClearPoint , SmartFlow , SmartFrame , SmartGrid , Inflexion , ClearPoint Maestro , SmartFrame Array , SmartFrame OR , ClearPoint Neuro Orchestra , ClearPoint Prism , ClearPointer , When Your Path is Unclear, We Point The Way , ClearPoint Advanced Laboratories , IRRAS , and IRRAFLOW are all trademarks of ClearPoint Neuro, Inc.
All statements, other than statements of historical fact, in this Annual Report, including statements relating to our expectations for performance, revenues and costs, and the adequacy of cash and cash equivalent balances and short-term investments to support operations and meet future obligations, are forward-looking statements.
We caution you that the forward-looking statements in this report are based on a combination of facts, factors currently known by us and our projections of the future, about which we cannot be certain.
In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
+7 more — sign up free →
REMOVED
52 Trademarks, Trade Names and Service Marks ClearPoint Neuro , ClearPoint , SmartFlow , SmartFrame , SmartGrid , Inflexion , SmartTwist , SmartTip , ClearPoint Maestro , SmartFrame Array , SmartFrame OR , ClearPoint Neuro Orchestra , ClearPoint Prism , SmartFlow Flex , ClearPointer , When Your Path is Unclear, We Point The Way , and ClearPoint Advanced Laboratories are all trademarks of ClearPoint Neuro, Inc.
The forward-looking statements relate to our expectations for performance, revenues and costs, and the adequacy of cash and cash equivalent balances and short-term investments to support operations and meet future obligations.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain.
Our ClearPoint system may not achieve broad market adoption and our future business growth is dependent upon marketing and selling our ClearPoint system, and other new products, in the operating room.
Our internal manufacturing operations are generally conducted at a single location, which may limit our ability to provide an adequate supply of our products, and any disruption at our manufacturing facility could render us unable to produce our products, increase our expenses and decrease our revenue.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →